During the Cell Therapy Scientific Session , Dr. Marbn will present on the "Clinical Trials of Allogeneic Cardiac Stem Cells Post-MI and in Advanced Heart Failure ," including results from the completed Phase I cohort of the ALLSTAR trial, which evaluated the safety of the Company's lead heart failure product candidate CAP-1002, an allogeneic ... (more)
http://ift.tt/1hFABBi
http://ift.tt/1hFABBi
No comments:
Post a Comment